Alnylam Pharmaceuticals (ALNY) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on ...

Biopharmaceutical stock Alnylam Pharmaceuticals (NASDAQ:ALNY) is riding a tsunami of hope that a treatment for a rare heart condition receives Food & Drug Administration approval. Although it has several drugs already on the market, the biopharma is not yet profitable.But if Alnylam can gain expedited approval from the FDA for its RNA interference drug vutrisiran, that could change quickly. Alnylam stock soared 31% on positive Phase 3 trial news and continued rising afterward. Getting vutrisiran, which is m ...

Could Alnylam Pharmaceuticals (NASDAQ:ALNY) become a household name in 2024? At the very least, the company should be well known in the medical community. If you like to wager small amounts of money on biotechnology stocks, then you really ought to consider Alnylam Pharmaceuticals stock.As we’ll discuss in a moment, Alnylam Pharmaceuticals didn’t start off 2024 with perfect financials. However, a recent announcement indicates a breakthrough moment for Alnylam Pharmaceuticals and, potentially, for some heart ...

文章核心观点 - 生物技术行业具有广阔的市场前景,预计到2030年市场规模将达到3.88万亿美元 [1] - 投资者可以选择估值较低的生物科技股票,获得更大的上涨空间 [2][3] 公司总结 Bio-Techne - 总部位于明尼苏达州明尼阿波利斯,主要从事生命科学试剂、仪器和服务的研发、制造和销售,在基因组学领域具有重要地位 [4] - 过去4个季度的每股收益为0.46美元,与预期基本持平,但存在季度性波动 [5] - 目前股价估值为9.97倍去年销售额,低于去年的10.62倍,未来有望提升估值 [6] Gilead Sciences - 总部位于加州福斯特城,是一家生物制药公司,主要从事药物的发现、开发和商业化,在HIV/AIDS和COVID-19治疗领域有所建树 [8] - 财务表现较为稳定,过去4个季度每股收益为0.98美元,略高于预期 [9] - 目前股价估值为3.05倍去年销售额,低于去年的3.6倍,有望提升估值 [10][11] Exelixis - 总部位于加州阿拉米达,专注于难治性癌症的新药研发和商业化,主要产品为肾细胞癌治疗药物Cabometyx [12] - 财务表现略有欠佳,过去4个季度每股收益为0.16美元,低于预期 [13] - 目前股价估值为3.79倍去年销售额,低于去年的4.07倍,有望提升估值 [14][15] Alnylam Pharmaceuticals - 总部位于马萨诸塞州剑桥,专注于基于RNA干扰技术的新药研发,涉及多种疾病领域 [17] - 过去4个季度平均每股亏损0.67美元,但低于预期亏损 [18] - 目前股价估值为15.71倍去年销售额,低于去年的17.1倍,有望提升估值 [19][20] Harmony Biosciences - 总部位于宾夕法尼亚州普利茅斯米丁,专注于罕见和神经系统疾病治疗药物的商业化,主要产品为嗜睡症治疗药物Wakix [21] - 过去4个季度每股收益为0.58美元,略低于预期 [22] - 目前股价估值为3.06倍去年销售额,低于去年的4.05倍,有望提升估值 [23][24] Amgen - 总部位于加州千橡市,是一家大型药企,主要从事人类治疗药物的发现、开发、制造和销售 [25] - 财务表现稳健,过去4个季度每股收益为4.58美元,高于预期 [26] - 目前股价估值为5.66倍去年销售额,略高于去年的5.23倍,但未来销售有望增长 [27][28] Incyte - 总部位于特拉华州威尔明顿,专注于血液肿瘤和自身免疫疾病的新药研发和商业化,主要产品为骨髓纤维化治疗药物Jakafi [29] - 财务表现良好,过去4个季度每股收益为0.95美元,略低于预期 [30] - 目前股价估值为3.44倍去年销售额,低于去年的3.98倍,有望提升估值 [30][31][32]

UKRAINE - 2021/05/27: In this photo illustration, the Alnylam Pharmaceuticals logo seen on a ... [+] smartphone and a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesAlnylam Pharmaceuticals stock (NASDAQ: ALNY), a pharmaceutical company focused on RNA interference therapeutics for genetically defined diseases, has seen a significant rise of 60% in a week. This can be attributed to positive data from a late-stage clinical trial ...

Alnylam Pharmaceuticals (ALNY) hit a new 52-week high on Monday after it reported positive top-line results from a late-stage study evaluating Amvuttra (vutrisiran), an investigational RNAi therapeutic, for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy. The stock jumped 34.5% in response to the success of the study.Please note that Amvuttra is already approved in the United States for the treatment of adult patients with polyneuropathy of hereditary ATTR amyloidosis. It is a ...

Key TakeawaysAlnylam Pharmaceuticals announced a Phase-3 study of its treatment for a rare heart condition showed a significant reduction in deaths and recurrent cardiovascular events.The biopharmaceutical company said it would be seeking regulatory approval later this year, including asking the Food and Drug Administration for a priority review.The news sent shares of Alnylam soaring over 31% in early trading Monday. Shares of Alnylam Pharmaceuticals (ALNY) skyrocketed over 31% in early trading Monday afte ...

Follow Invezz on Telegram , Twitter , and Google News for instant updates >Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) opened more than 30% up on Monday after reporting promising results from a late-stage trial of its heart drug. Are you looking for signals & alerts from pro-traders? Sign-up to Invezz Signals™ for FREE. Takes 2 mins.Shares of the biopharmaceutical company are now trading at a year-to-date high of $220.  Why is it significant for Alnylam Pharmaceuticals stock?Copy link to sectionVutrisiran de ...

Alnylam Pharmaceuticals (ALNY) shares ended the last trading session 5.3% higher at $165.70. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 5.4% gain over the past four weeks.The sudden rise in the stock price has likely been driven by the growing optimism of investors regarding Amvuttra’s (vutrisiran) potential to earn increasing revenues for the company. The drug, approved for treating adult patients with polyne ...

文章核心观点 - 本文介绍了一系列"未被关注"的股票投资机会,涵盖了多个行业和公司[1][2][3] - 文章包括了一些强烈买入、持有和卖出的建议,并对相关公司的业务、财务状况等进行了分析[4][5][6][7][8][9][10][11][12] - 文章还提到了一些其他值得关注的公司和行业,如铀矿、能源等[13] 行业和公司总结 物流地产行业 - 物流地产公司Logistic Properties of the Americas(LPA)控制了730万平方英尺的A级物流房地产,主要专注于电子商务市场[4][5] - 尽管该公司有增长潜力,但目前股价被高估,且公司负债较高,在哥伦比亚的资产也存在潜在问题[4] 封闭式基金行业 - 通用美国投资公司(GAM)是一家封闭式基金,投资于主要为大盘美股的多元化股票组合,过去表现良好[6][7] - 该基金使用约12%的杠杆,以优先股形式,每季度支付5.95%的分红,适合长期持有的收益型投资者[6][7] 生物科技行业 - CRISPR Therapeutics(CRSP)的基因疗法产品Casgevy已获美国批准,用于治疗地中海贫血和镰状细胞贫血[7] - 尽管公司管理层审慎控制了运营费用,延长了现金流,但该公司的投资仍具有投机性质[7] 电池技术行业 - Enovix(ENVX)在电池制造方面取得了重要进展,已经能够生产出优于市场上其他电池的样品,并吸引了主要智能手机厂商的兴趣[8] - 不过该公司在成为领先电池公司之前,仍需要解决很多执行问题[8] 基因治疗行业 - Voyager Therapeutics(VYGR)专注于开发治疗神经系统疾病的基因疗法,已经提交了VY-TAU01的IND申请并获得FDA快速批准[9] - 这是投资者期待已久的一个重要里程碑,表明公司的管线取得了良好进展[9] 能源和资源行业 - Adams Natural Resources Fund(PEO)是一只主要投资于能源和自然资源股票的封闭式基金,目前交易折价14%[10][11] - 该基金过去一年涨幅超过13%,是投资能源行业的理想选择,可以获得较高的分红收益[10][11] 人工智能设备行业 - POET Technologies(POET)是一家专注于人工智能设备的公司,最近获得了富士康的重要设计订单,并成功进行了股权融资[11][12] - 这些进展降低了公司的融资风险,提升了其商业化前景,因此评级被上调为强烈买入[11][12] 其他公司和行业 - 铀矿公司Uranium Royalty(UROY,URC:CA)的估值看起来较为合理,如果铀价重新走强,投资者或许能获得一些收益[13] - 施氏(Halliburton,HAL)的股价看起来相对便宜,但其利润率可能难以维持在当前水平[13] - 克洛维健康(Clover Health,CLOV)的股价存在120%的上涨空间[13] - 阿尔尼拉姆制药(Alnylam Pharmaceuticals,ALNY)即将公布HELIOS-B研究的临床数据,这将对股价产生重大影响[13] - 罗文特科学(Roivant Sciences,ROIV)的市值为83.7亿美元,现金储备60亿美元,股价被低估[13]